168 related articles for article (PubMed ID: 20188551)
1. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
[TBL] [Abstract][Full Text] [Related]
3. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.
Bursavich MG; Brooijmans N; Feldberg L; Hollander I; Kim S; Lombardi S; Park K; Mallon R; Gilbert AM
Bioorg Med Chem Lett; 2010 Apr; 20(8):2586-90. PubMed ID: 20303263
[TBL] [Abstract][Full Text] [Related]
4. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
5. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Kaplan J; Verheijen JC; Brooijmans N; Toral-Barza L; Hollander I; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Jan; 20(2):640-3. PubMed ID: 19963384
[TBL] [Abstract][Full Text] [Related]
8. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
9. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
11. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
13. 5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer.
Zhang N; Ayral-Kaloustian S; Anderson JT; Nguyen T; Das S; Venkatesan AM; Brooijmans N; Lucas J; Yu K; Hollander I; Mallon R
Bioorg Med Chem Lett; 2010 Jun; 20(12):3526-9. PubMed ID: 20483602
[TBL] [Abstract][Full Text] [Related]
14. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
Richard DJ; Verheijen JC; Zask A
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
[TBL] [Abstract][Full Text] [Related]
16. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha.
Richard DJ; Verheijen JC; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Apr; 20(8):2654-7. PubMed ID: 20223664
[TBL] [Abstract][Full Text] [Related]
17. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T
Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
